Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-4632.2011.04955.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Clinicopathologic and Molecular Reappraisal of Myxoinflammatory Fibroblastic Sarcoma-A Controversial and Pathologically Challenging Low-Grade Sarcoma.
Genes Chromosomes Cancer
January 2025
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Purpose: Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare, low-grade sarcoma affecting with predilection the acral soft tissues of middle-aged adults. Clinically, MIFS is associated with a high rate of local recurrence but infrequent distant metastases. The diagnosis remains challenging due to their wide histologic spectrum and overlap with reactive, benign, and low-grade malignant lesions.
View Article and Find Full Text PDFSuperficial acral fibromyxoma on the palm: a case report.
J Med Case Rep
January 2025
Department of Clinical Medicine, Jining Medical University, Jining, China.
Background: Superficial acral fibromyxoma is a noncancerous, benign tumor of soft tissue with an unidentified origin. Occurrences of abnormalities on the palm are less frequently documented.
Case Report Presentation: A 47-year-old East Asian woman presented with a palm tumor on her left knuckle that had been present for 4 months.
Defining high-risk patients: beyond the 8the AJCC melanoma staging system.
Arch Dermatol Res
December 2024
Department of Medical and Surgical Science (DIMEC), University of Bologna, Bologna, 40138, Italy.
Article Synopsis
- - Melanoma cases are on the rise, leading to frequent updates in guidelines for diagnosis, staging, and treatment; recent approvals now include adjuvant therapy for stage IIb/c melanoma.
- - A study involving 92 melanoma patients revealed that those with stage IIb/c have a later age of diagnosis and a higher occurrence of specific characteristics like ulceration and angiotropism compared to stage IIIa patients.
- - While not statistically significant, stage IIb/c patients showed a higher rate of metastasis over a 5-year period (15%) compared to those with stage IIIa melanoma (4%), highlighting the potential benefits of adjuvant immunotherapy for stage IIb/c patients.
Tenosynovitis with psammomatous calcifications: Series of 18 cases and review of the literature emphasizing a common source of expert consultation and updated differential diagnosis.
Virchows Arch
December 2024
Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg Building 2245, Baltimore, MD, 21231, USA.
Article Synopsis
- - Tenosynovitis with psammomatous calcifications (TPC) is a rare, non-cancerous condition that often affects women and is thought to result from repetitive use or trauma, commonly appearing at sites like the hands, feet, and wrists.
- - In a study involving 18 new cases, most patients presented with painful masses, and imaging often showed benign characteristics, but many of these cases were misdiagnosed as more serious conditions like gout or tumors.
- - Follow-up on patients (mostly for around 30 months) showed no local recurrences after surgical removal, highlighting the necessity for greater awareness among medical professionals regarding TPC.
A cross-sectional study of physiologic volar melanotic macules: Demographic, historical, clinical, and dermatoscopic features of a common yet neglected pigmentary variant in individuals with skin of color.
J Am Acad Dermatol
November 2024
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts. Electronic address:
Background: Physiologic volar melanotic macules (P-VMM) are understudied. Trauma has been suggested as a predisposing factor. Little has been published over the last several decades.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!